Tectonic Therapeutic, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Completing a clinical trial enrollment shows progress toward developing a new medicine for heart disease patients.
Quarterly earnings reports show whether a company is spending money wisely and staying on track with its plans.
Quarterly reports provide detailed financial statements showing a company's cash, expenses, and progress.
Personnel changes can affect how well a company is managed and whether it achieves its goals.
Year-end earnings show the full picture of a company's financial health and operational results.
Annual reports provide complete financial data for the entire year, showing long-term company performance.
Corporate presentations explain company strategy and personnel moves signal leadership changes that affect future direction.
Stocky reads Tectonic Therapeutic, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Tectonic Therapeutic, Inc.'s most recent tracked filing was a 8-K on 10 Jun 2026: Completes enrollment in TX45 APEX Phase 2 trial.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.